Phase 2 N=81 Memantine and Naltrexone Treatment for Opioid Dependence
Opioid Dependence
Primary: Retention in Treatment — 7; 5; 6 participants — p=0.32
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
Phase 2 N=10 Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans
Opiate Addiction
Primary: Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue or Post-neutral - Via the Visual Analog Scale for Craving (VASC) — 2.67; 0.83; -0.33; -0.17 units on…
Phase 3 N=55 Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
Opioid Dependence · Heroin Dependence
Primary: Opiate Use Measured by Urine Toxicology Results — 9; 10 Percent of total urine samples
Phase 3 N=74 Smoking Cessation & Opioid Dependence Treatment Integration
Smoking Cessation · Opioid Related Disorders
Primary: Recruitment, Assignment to Treatment, and Retention Rates — 40; 33; 15; 32 Participants
Phase 2 N=12 Oxytocin Treatment of Opioid Dependence
Opioid Dependence · Opioid Withdrawal
Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours
Phase 2 N=42 Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans
Opiate Addiction
Primary: Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue (30 Minutes), and From Test Day 1 Through Test Day 4 (1 Week)) - Via the Visual Analog Scale for…
N/A N=133 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Opioid Withdrawal · Physical Dependence
Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87
Phase 2 N=70 Treatment for Cannabis Withdrawal and Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg
Phase 4 N=188 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)
Opiate Dependence · Drug Dependence · Substance Dependence
Primary: Responders at Day 3 — 85; 85; 8; 9 Participants
N/A N=329 Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department
Opiate Addiction
Primary: Self-reported Engagement in Formal Substance Abuse Treatment at 30 Days (Verified by Contact With the Treatment Program) — 4.99; 5.67; 3.71 Mean Number of Outpatient…
Phase 3 N=21 Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence
Opioid Addiction
Primary: Changes in Resting State Disorganization Between Baseline and One Week by Person by Lapsed Category — 0.315; 0.328; 0.384; 0.394 Mean default mode network (DMN) z-scores
Phase 3 N=306 Addiction Treatment in Russia: Oral vs. Naltrexone Implant
Heroin Dependence · Opioid-Related Disorders
Primary: Retention Without Relapse to Heroin Addiction (Measured at Month 6) — 54; 16; 11 Participants
Phase 2 N=12 A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
Opioid Abuse · Opioid Dependence
Primary: Mean Peak Opioid Withdrawal Assessed by the Clinical Opiate Withdrawal Scale (COWS) — 12.6; 1.3 units on a scale
Phase 4 N=12 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
Chronic Pain
Primary: 3 Scores on the Addiction Research Center Inventory (ARCI) — 7.6; 5.4; 5.2; 3.3 scores on a scale
Phase 4 N=113 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
Opiate Dependence
Primary: Illicit Opioid Use — 35.2; 53.2 percent of opioid negative urine samples
Phase 3 N=9 Buprenorphine Treatment for Opioid Dependence
Opioid Dependence
Primary: Urine Toxicology for Opiate Use — 2; 4; 2; 0 Participants
Phase 2 N=84 The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
Opioid Dependence
Primary: Percent of Weekly Urine Samples Negative for Opiates — 64.5; 81.3; 71.1; 66.7 percentage of negative urine samples — p=0.48
Phase 4 N=19 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Low Back Pain
Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097
Phase 2 N=81 Medications for Stopping Cocaine Dependence and Preventing Relapse
Cocaine Abuse · Cocaine-Related Disorders
Primary: Mean Percentage of Cocaine-positive Urines Over Course of 12 Week Treatment in Subgroup Achieving Abstinence at Baseline — 31; 28; 47; 35 Mean % of cocaine-positive urines
Phase 4 N=25 Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging
Nicotine Dependence
Primary: Change in Mu-opioid Receptor Binding Potential (BP) Between Baseline and Post-patch Scans — -2.47; -5.94; 5.60; -1.24 ratio
N/A N=87 Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
HIV Prevention · Opioid-Related Disorders
Primary: Treatment Engagement — 23; 11; 6 participants — p=<0.001
Phase 3 N=211 Methadone Maintenance for Prisoners
Heroin Addiction
Primary: Treatment Retention in the Community — 23.1; 91.3; 166.0 Days in community treatment
N/A N=106 Cocaine Withdrawal and Pharmacotherapy Response
Cocaine Dependence · Opiate Dependence
Primary: Percent Days Abstinent From Cocaine - Self Report — 72.9; 72.9; 59.3 percentage of days — p=.10
Phase 3 N=117 Improving Treatment Outcomes for Prescription Opioid Dependence
Drug Dependence
Primary: Detoxification Phase: Changes in Percent of Illicit Opioid-positive Urine Samples Over Time — 35.0; 41.6 percentage of urine positive samples — p=0.77
N/A N=150 Intensive Models of HCV Care for Injection Drug Users
Hepatitis C · Medication Adherence
Primary: Electronically Monitored Medication Adherence — 86; 80; 75 Percentage of medication taken
N/A N=533 A Digital Intervention to Prevent the Initiation of Opioid Misuse in Adolescents in School-based Health Centers
Opioid Misuse
Primary: Percentage Reporting 'Great Perceived Risk of Harm' From Opioid Misuse — 66; 53 Participants
N/A N=9 Aprepitant Effects on Oxycodone Response
Narcotic Abuse
Primary: Abuse Liability Proxy — 0.197; 0.483; 0.159; 7.678 units on a scale (points 0-100) — p=<.05
Phase 3 N=20 Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial
Opioid-Related Disorders · Heroin Dependence
Primary: The Primary Outcome Will Include a Comparison of the Proportion of Patients Successfully Inducted One Week After the Initial Primary Care Visit. — 6; 6 participants
Phase 2 N=31 Carvedilol for Psychostimulant Dependence
Cocaine Dependence · Cocaine Withdrawal
Primary: Urine Toxicology Screens — 38.33; 41.85 percentage of cocaine negative urines — p=0.05